Plasmin inhibitors and fibrinogen breakdown during the initial phase of thrombolytic treatment--the problem of the alpha 2-antiplasmin determination.
During the first 3 hr of thrombolytic treatment with porcine plasmin (p-PL) or streptokinase (SK) a rapid decrease of clottable fibrinogen with generation of large amounts of fibrin(-ogen) degradation products (FDP) are found. alpha 2-antiplasmin (alpha 2AP) is rapidly neutralized. Whereas in patients treated with SK more than half of the original plasminogen was consumed, its level remained unchanged during p-PL infusion. When alpha 2AP reaches values below some 20%, spontaneous amidolytic activity towards S-2251 representing either PL-alpha 2-macroglobulin- or SK-plasminogen-complex activity appears. This activity has to be considered in the alpha 2AP assay in order to avoid underestimation of this inhibitor.
D000818:Animals; D005341:Fibrinolysin / Q000032:analysis / Q000627:therapeutic use*; D005343:Fibrinolytic Agents; D006801:Humans; D007700:Kinetics; D013300:Streptokinase / Q000627:therapeutic use*; D013552:Swine; D013924:Thrombophlebitis / Q000188:drug therapy*; D013997:Time Factors; D000979:alpha-2-Antiplasmin / Q000032:analysis*
D005343:Fibrinolytic Agents; D000979:alpha-2-Antiplasmin; D013300:Streptokinase; D005341:Fibrinolysin